1. Home
  2. PHVS vs TMP Comparison

PHVS vs TMP Comparison

Compare PHVS & TMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • TMP
  • Stock Information
  • Founded
  • PHVS 2015
  • TMP 1836
  • Country
  • PHVS Switzerland
  • TMP United States
  • Employees
  • PHVS N/A
  • TMP N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • TMP Major Banks
  • Sector
  • PHVS Health Care
  • TMP Finance
  • Exchange
  • PHVS Nasdaq
  • TMP Nasdaq
  • Market Cap
  • PHVS 980.9M
  • TMP 878.2M
  • IPO Year
  • PHVS 2021
  • TMP N/A
  • Fundamental
  • Price
  • PHVS $22.32
  • TMP $66.04
  • Analyst Decision
  • PHVS Buy
  • TMP Buy
  • Analyst Count
  • PHVS 6
  • TMP 2
  • Target Price
  • PHVS $37.17
  • TMP $69.00
  • AVG Volume (30 Days)
  • PHVS 33.8K
  • TMP 57.3K
  • Earning Date
  • PHVS 08-13-2025
  • TMP 07-25-2025
  • Dividend Yield
  • PHVS N/A
  • TMP 3.67%
  • EPS Growth
  • PHVS N/A
  • TMP 980.13
  • EPS
  • PHVS N/A
  • TMP 5.16
  • Revenue
  • PHVS N/A
  • TMP $297,067,000.00
  • Revenue This Year
  • PHVS N/A
  • TMP $13.79
  • Revenue Next Year
  • PHVS N/A
  • TMP $6.90
  • P/E Ratio
  • PHVS N/A
  • TMP $12.79
  • Revenue Growth
  • PHVS N/A
  • TMP 40.19
  • 52 Week Low
  • PHVS $11.51
  • TMP $49.28
  • 52 Week High
  • PHVS $25.76
  • TMP $79.01
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 73.31
  • TMP 59.64
  • Support Level
  • PHVS $17.63
  • TMP $66.22
  • Resistance Level
  • PHVS $19.00
  • TMP $67.89
  • Average True Range (ATR)
  • PHVS 1.20
  • TMP 1.44
  • MACD
  • PHVS 0.35
  • TMP 0.38
  • Stochastic Oscillator
  • PHVS 92.15
  • TMP 75.56

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About TMP Tompkins Financial Corporation

Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.

Share on Social Networks: